title: Inhibition by Tranilast of the Synergistic Induction of Degranulation and IL-13 Expression by IL-33 and FcɛRI Cross-linking in Mast Cells.
abstract: OBJECTIVE
  To assess the effects of tranilast on degranulation and IL-13 production in mast cells activated by IL-33 and cross-linking of FcɛRI.
  
  
  METHODS
  Bone marrow-derived mast cells (BMMCs) were sensitized with anti-DNP IgE. Sensitized cells were pretreated with tranilast and further stimulated with DNP-BSA, IL-33, or a combination of DNP-BSA and IL-33. Degranulation and the level of IL-13 release and mRNA expression in BMMCs were measured.
  
  
  RESULTS
  Simultaneous stimulation with DNP-BSA and IL-33 resulted in marked increase in β-hexosaminidase release. Tranilast significantly inhibited degranulation of BMMCs in the condition of combined treatment of DNP-BSA and IL-33. Combination of DNP-BSA and IL-33 induced a pronounced increase in the IL-13 release and mRNA expression. Tranilast significantly inhibited IL-13 release and mRNA expression in BMMCs stimulated by DNP-BSA and IL-33.
  
  
  CONCLUSIONS
  Tranilast has efficacy on the inhibition of degranulation and IL-13 production in BMMCs induced by the combination of DNP-BSA and IL-33.
authors.affiliation: a Research Village Kyoto , Rohto Pharmaceutical Co. Ltd ., Kizugawa City, Kyoto , Japan.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Tsuji
authors.affiliation: b Department of Ophthalmology and Visual Science , Kochi Medical School , Nankoku City, Kochi , Japan.
authors.forename: Ken
authors.initials: K
authors.lastname: Fukuda
authors.affiliation: b Department of Ophthalmology and Visual Science , Kochi Medical School , Nankoku City, Kochi , Japan.
authors.forename: Atsuki
authors.initials: A
authors.lastname: Fukushima
mesh_terms: D000818:Animals; D001854:Bone Marrow Cells / Q000378:metabolism; D015550:Cell Degranulation / Q000187:drug effects*; D003432:Cross-Linking Reagents; D004140:Dinitrophenols / Q000494:pharmacology; D004357:Drug Synergism; D006634:Histamine H1 Antagonists / Q000494:pharmacology*; D018793:Interleukin-13 / Q000235:genetics / Q000378:metabolism*; D000067596:Interleukin-33 / Q000494:pharmacology*; D008407:Mast Cells / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D012333:RNA, Messenger / Q000378:metabolism; D017455:Receptors, IgE / Q000276:immunology*; D012710:Serum Albumin, Bovine / Q000494:pharmacology; D001619:beta-N-Acetylhexosaminidases / Q000378:metabolism; D062367:ortho-Aminobenzoates / Q000494:pharmacology*
chemical_list: D003432:Cross-Linking Reagents; D004140:Dinitrophenols; D006634:Histamine H1 Antagonists; C506535:Il33 protein, mouse; D018793:Interleukin-13; D000067596:Interleukin-33; D012333:RNA, Messenger; D017455:Receptors, IgE; C034638:dinitrophenyl-bovine serum albumin; D062367:ortho-Aminobenzoates; D012710:Serum Albumin, Bovine; D001619:beta-N-Acetylhexosaminidases; C012293:tranilast